A Phase Ib Investigation of the Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Sirolimus (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Aug 2019 Planned initiation date changed from 30 Sep 2018 to 30 May 2019.
- 12 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Sep 2018 New trial record